Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ: UTHR )

366.61 +4.28 (+1.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
From United Therapeutics Corporation
Via Business Wire
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor
Although several companies have seen their valuations blossom, you can still find bargain stocks if you know where to look. 
Via InvestorPlace
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024
Learn about these undervalued NASDAQ stocks teeming with the potential to bounce back and show great returns for investors this year. 
Via InvestorPlace
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Earnings Outlook For United Therapeutics
Via Benzinga
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward. 
Via InvestorPlace
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings
Legal battle unfolds as United Therapeutics challenges FDA's handling of Liquidia's drug approval process. Explore the implications on PH-ILD, potential 30-month stay, and recent financial... 
Via Benzinga
Exposures Product Safety
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
From United Therapeutics Corporation
Via Business Wire
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions. 
Via InvestorPlace
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Liquidia: Court victory the awakening of an industry giant?
Liquidia's stock surged after an enormous court win against United Therapeutics, accompanied by analyst upgrades and insider buying. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?
Liquidia Corp (NASDAQ: LQDA) stock jumped after a win in a pat 
Via Benzinga
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
From United Therapeutics Corporation
Via Business Wire
United Therapeutics and Miromatrix Medical Announce Successful Tender Offer
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024
From United Therapeutics Corporation
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eargo, Inc. (Nasdaq – EAR), Miromatrix Medical, Inc. (Nasdaq – MIRO), Physicians Realty Trust (NYSE – DOC), Spirit Realty Capital (NYSE – SRC)
From Brodsky & Smith LLC
Via GlobeNewswire
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Flying Car Stocks: What a Devastating Short Report Means for EHang
Hindenburg raised red flags for flying car stocks after releasing a short report on EH stock. Here's what investors should watch. 
Via InvestorPlace
EH Stock Alert: Hindenburg Slams EHang in New Short Report
EH stock is falling back to earth after Hindenburg Research issued a short report on the electric vertical take-off and landing (eVTOL) firm. 
Via InvestorPlace
United Therapeutics Corporation Reports Third Quarter 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.